Patents Assigned to Stealth Peptides International, Inc.
-
Publication number: 20150320824Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof, and performing a coronary artery bypass graft procedure on the subject.Type: ApplicationFiled: April 4, 2014Publication date: November 12, 2015Applicant: Stealth Peptides International, Inc.Inventors: Kenneth Borow, D. Travis Wilson
-
Publication number: 20150157685Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.Type: ApplicationFiled: July 31, 2013Publication date: June 11, 2015Applicant: Stealth Peptides International, Inc.Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
-
Patent number: 9023807Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: GrantFiled: May 17, 2013Date of Patent: May 5, 2015Assignee: Stealth Peptides International, Inc.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
-
Publication number: 20150118315Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.Type: ApplicationFiled: June 13, 2012Publication date: April 30, 2015Applicant: Stealth Peptides International, Inc.Inventor: D. Travis Wilson
-
Publication number: 20150065437Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: ApplicationFiled: March 20, 2014Publication date: March 5, 2015Applicant: Stealth Peptides International, Inc.Inventors: Liping Liu, Lawrence Gu
-
Publication number: 20150018288Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 21, 2013Publication date: January 15, 2015Applicant: Stealth Peptides International, Inc.Inventors: D. Travis Wilson, K. George Mooney, Peter J. Oates
-
Publication number: 20140364370Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.Type: ApplicationFiled: February 20, 2014Publication date: December 11, 2014Applicant: Stealth Peptides International, Inc.Inventor: D. Travis Wilson
-
Publication number: 20140349941Abstract: The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, apoptosis inhibition and electrical conductance.Type: ApplicationFiled: May 22, 2014Publication date: November 27, 2014Applicants: Cornell University, Stealth Peptides International, Inc.Inventors: D. Travis Wilson, Hazel Szeto, Alex Birk
-
Publication number: 20140341879Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof wherein the peptide is D-Arg-26-Dmt-Lys-Phe-NH2 (SS-31).Type: ApplicationFiled: January 7, 2014Publication date: November 20, 2014Applicant: Stealth Peptides International, Inc.Inventors: Kenneth Borow, D. Travis Wilson
-
Patent number: 8697657Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.Type: GrantFiled: March 15, 2011Date of Patent: April 15, 2014Assignee: Stealth Peptides International, Inc.Inventor: D. Travis Wilson
-
Publication number: 20140093897Abstract: The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport and electrical conductance.Type: ApplicationFiled: March 22, 2012Publication date: April 3, 2014Applicants: Stealth Peptides International, Inc., Cornell UniversityInventors: Hazel H. Szeto, Alexander V. Birk, D. Travis Wilson
-
Publication number: 20130190244Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.Type: ApplicationFiled: December 30, 2010Publication date: July 25, 2013Applicant: Stealth Peptides International, Inc.Inventors: Kenneth Borow, D. Travis Wilson
-
Patent number: 8470784Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: GrantFiled: August 23, 2010Date of Patent: June 25, 2013Assignee: Stealth Peptides International, Inc.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
